TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Renalytix ( (GB:RENX) ).
Renalytix has confirmed the receipt of £860k in Research and Development Tax Credits for work completed in the fiscal years ending June 2023 and June 2024. This financial boost is expected to support the company’s ongoing operations and enhance its industry positioning as a leader in kidney disease diagnostics. The receipt of these credits underscores the company’s commitment to innovation and may have positive implications for stakeholders by reinforcing the financial stability and continued development of its prognostic tools.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.
Renalytix’s overall stock score is low due to severe financial challenges, including declining revenues, high operating losses, and solvency issues. Despite positive corporate events suggesting strategic interest and growth potential, the technical analysis and valuation remain weak, impacting the stock’s appeal.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. The company has developed kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test for early-stage risk assessment in chronic kidney disease, which is commercially available in the United States.
YTD Price Performance: -21.86%
Average Trading Volume: 4,864,204
Technical Sentiment Signal: Sell
Current Market Cap: £36.71M
See more insights into RENX stock on TipRanks’ Stock Analysis page.